BRIAN C. ROGERS is the Chairman of T. Rowe Price Group where he has worked since 1982. He received an AB from Harvard College and an MBA from Harvard Business School. Brian is a trustee of Johns Hopkins University and Johns Hopkins Medicine, and is a board member of several other non-profit organizations. He is also a director of United Technologies Corporation. MARY JO serves on the Board of Directors of the Melanoma Research Alliance, and is also a peer to peer counselor for patients who are currently battling melanoma. In addition to supporting MRA, Mary Jo sits on the board of Cristo Rey Jesuit High School in Baltimore, as well as a local community association and other smaller organizations. Mary Jo graduated from Emmanuel College with a BA in Political Science. She currently lives in Baltimore with her husband, and they have three children, Hilary, Peter, and Sydney.
Mary Jo Rogers Professorship in Cancer Immunology and Melanoma Research
School of Medicine
Established in 2016 by Mary Jo and Brian Rogers
Held by William Sharfman
Dr. WILLIAM SHARFMAN is the inaugural recipient of the Mary Jo Roger Professorship in Cancer Immunology and Melanoma Research. He received his Bachelor of Arts degree from Yeshiva University in New York City in 1979, and his medical degree from the Medical College of Ohio at Toledo in 1982. He completed his internship and residency at Cleveland Clinic Hospital from 1982-1985. He continued on to complete a fellowship in Hematology and Oncology at the Cleveland Clinic Hospital from 1986 to 1989. From 1989 to 1992 he served as a Senior Investigator in the Biologic Response Modifier Program of the National Cancer Institute, after which he joined the faculty of the Johns Hopkins University, School of Medicine.
Dr. Sharfman was a founding member of the Johns Hopkins Melanoma Group that was established in 1995. Currently, Dr. Sharfman is an Associate Professor of Oncology and Dermatology at the Johns Hopkins University, Director of Cutaneous Oncology at the Johns Hopkins Kimmel Cancer Center, and Clinical Co-Director of the Hopkins Melanoma Program.
Dr. Sharfman is interested in the management of complicated patients with cutaneous malignancies. His research focuses on novel therapies for high risk and advanced melanoma patients. Currently, he leads clinical trials studying braf inhibitors, anti-CTLA4, peptide vaccines, PD-1 inhibitors. Dr. Sharfman is also involved in the care of patients with sarcomas, gastrointestinal tumors, non-melanoma skin cancers, and cancers of unknown primary sites.